- Home
- IHS vs BCAX Comparison
IHS vs BCAX Comparison
Compare IHS & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- BCAX
- Stock Information
- Founded
- IHS 2001
- BCAX 2018
- Country
- IHS United Kingdom
- BCAX United States
- Employees
- IHS N/A
- BCAX N/A
- Industry
- IHS Telecommunications Equipment
- BCAX
- Sector
- IHS Telecommunications
- BCAX
- Exchange
- IHS Nasdaq
- BCAX NYSE
- Market Cap
- IHS 979.2M
- BCAX 1.0B
- IPO Year
- IHS 2021
- BCAX 2024
- Fundamental
- Price
- IHS $2.98
- BCAX $18.09
- Analyst Decision
- IHS Strong Buy
- BCAX Strong Buy
- Analyst Count
- IHS 7
- BCAX 4
- Target Price
- IHS $9.07
- BCAX $41.00
- AVG Volume (30 Days)
- IHS 375.9K
- BCAX 335.7K
- Earning Date
- IHS 11-12-2024
- BCAX 11-12-2024
- Dividend Yield
- IHS N/A
- BCAX N/A
- EPS Growth
- IHS N/A
- BCAX N/A
- EPS
- IHS N/A
- BCAX N/A
- Revenue
- IHS $1,783,187,000.00
- BCAX N/A
- Revenue This Year
- IHS N/A
- BCAX N/A
- Revenue Next Year
- IHS $2.40
- BCAX N/A
- P/E Ratio
- IHS N/A
- BCAX N/A
- Revenue Growth
- IHS N/A
- BCAX N/A
- 52 Week Low
- IHS $2.18
- BCAX $17.41
- 52 Week High
- IHS $5.28
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- IHS 56.83
- BCAX N/A
- Support Level
- IHS $2.71
- BCAX N/A
- Resistance Level
- IHS $2.94
- BCAX N/A
- Average True Range (ATR)
- IHS 0.17
- BCAX 0.00
- MACD
- IHS 0.03
- BCAX 0.00
- Stochastic Oscillator
- IHS 92.24
- BCAX 0.00
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, most of who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.